Luxturna 5000000000000 Vg (Voretigene Neparvovec SOLUTION) 5000000000000 VG

Voretigene neparvovec works by delivering a functional copy of the RPE65 gene to retinal pigment epithelial cells via an adeno-associated virus (AAV) vector. This gene therapy restores the visual cycle in patients with biallelic RPE65 mutations, enabling the production of proteins necessary for vision.

The dose of Luxturna is determined by a healthcare provider based on the patient's specific condition and needs. It is administered as a subretinal injection after vitrectomy in each eye. The exact dosage and administration schedule should be discussed with a healthcare professional.

The safety of Luxturna during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider to discuss the potential risks and benefits before using Luxturna in these situations.

To order Luxturna from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will reply with pricing, availability, shipping, and the import paperwork.

Luxturna is a pioneering gene therapy that offers a unique approach to treating inherited retinal dystrophy by directly addressing the genetic mutation. Unlike other treatments that may only manage symptoms, Luxturna aims to restore vision by delivering a functional copy of the RPE65 gene to retinal cells.

Luxturna should be stored and transported frozen at ≤-65 ºC. Once thawed, the medicine should not be re-frozen and should be left at room temperature (below 25 °C). It is important to follow the storage instructions provided by the healthcare professional to ensure the efficacy and safety of the medication.

Luxturna is administered as a subretinal injection after vitrectomy in each eye. The procedure is performed by a specialist in ophthalmology. The injection is given directly under the retina, the thin light-sensing layer at the back of the eye. The injections will happen one eye at a time, on two different dates separated by at least six days.

The most serious risks associated with Luxturna include retinal detachment, bleeding in the retina, and permanent decline in the sharpness of vision. Patients should be monitored for any signs of these complications and should seek immediate medical attention if they experience any adverse effects.

Luxturna is not suitable for everyone. Patients who do not have mutations in the RPE65 gene or who do not have sufficient viable retinal cells may not benefit from this treatment. It is important to undergo genetic testing to confirm eligibility for Luxturna. Additionally, patients with certain eye conditions or allergies to any of the components of Luxturna should avoid using this medication.